Clinical Trial Update: Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Osimertinib plus chemotherapy with optimized site-directed primary tumor therapy to improve outcomes in non-small cell lung cancer. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: Pusan National University Hospital | Conditions: Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor | Phase 2 | Status: RECRUITING